Q2 2025 MariMed Inc Earnings Call Transcript
Key Points
- MariMed Inc (MRMD) achieved sequential growth in both wholesale and retail revenues during the second quarter.
- The company reported a substantial increase in EBITDA and maintained a healthy balance sheet.
- MariMed Inc (MRMD) successfully launched adult-use sales in Delaware, which is expected to broaden their customer base and amplify revenue.
- The company expanded its market presence with a new management services agreement in Pennsylvania, which will contribute to top-line growth and margins.
- MariMed Inc (MRMD) continues to innovate with new products like MycroDose, which exceeded sales expectations in Massachusetts.
- The company faces ongoing challenges from pricing pressures, market saturation, and lack of federal reform in the cannabis industry.
- Performance in Missouri did not meet expectations, prompting the company to evaluate options to improve profitability.
- The transition to a new seed-to-sale platform in Illinois temporarily impacted wholesale revenue.
- Retail revenue declined 5% year-over-year, partly due to increased competition near the Metropolis dispensary.
- Non-GAAP adjusted gross margins declined year-over-year due to a shift in revenue mix and ramp-up costs in Missouri.
Good morning. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the MariMed Inc., second quarter 2025 financial results conference call. (Operator Instructions) I will now turn the line over to Jake Dean, Director of Research and Development. Please go ahead.
Hello, and good morning, everyone. I'm Jake Dean, Director of Research and Development at MariMed. I'm very proud of the contributions my team has made in supporting the growth of our company. We work hard to identify new and innovative product opportunities and make sure all of our products are consistent, delicious and meet our very high standards for quality. I'm honored to kick off today's 2025 second quarter earnings call. Joining the call today are Jon Levine, our Chief Executive Officer; Mario Pinho, our Chief Financial Officer; and Ryan Crandall, our Chief Commercial Officer.
This call will be archived in our Investor Relations website and contains forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
